Instagram began tests that hide "like" counts on posts. That means influencers who market products on Instagram will have to rely on different metrics to show success.Technologyread more
Peter Neupert worked for Microsoft and Amazon-backed Drugstore.com, where he got to know Jeff Bezos. He now advises start-ups.Technologyread more
Disney's "Avengers: Endgame" is now the highest-grossing film of all time having earned $2.79 billion at the global box office.Entertainmentread more
Regional stability, oil prices and potential for war will all depend on what Iran does with its nuclear program in the event of the deal's termination.World Politicsread more
Facebook Vice President David Marcus is the face of the company's Libra digital currency, but the original driving force was a 26-year-old female corporate-development...Technologyread more
Moving lots of data to a public cloud over the internet can take months or years. CNBC got an inside look at how AWS transfers data to the cloud for its clients.Technologyread more
Amazon's new policy for account suspensions doesn't go far enough to protect sellers from potentially unfair and wrongful suspensions, merchants say.Technologyread more
There is no end in sight to the Boeing 737 Max grounding after two fatal crashes, prompting airlines to rethink their growth plans.Airlinesread more
After a year of flooding, Midwest farmers face a stifling heat wave that's spreading across the U.S.Weather & Natural Disastersread more
On Saturday, Disney's Marvel Studios announced its upcoming slate of superhero films during a panel at San Diego Comic-Con.Entertainmentread more
"It troubles me that the most important political office in the world is becoming the face of racism and exclusion," Kaeser said in a Twitter post.Politicsread more
CytRx shares tanked nearly 60 percent after the company said a late-stage trial showed one of its cancer treatments did not perform better than other drugs.
The biopharmaceutical research and development company performed clinical trials to "evaluate the efficacy and safety of aldoxorubicin as a second-line treatment for patients with soft tissue sarcomas," the company said in a press release.
The results did not meet expectations.
"This analysis did not provide for sufficient follow-up for the nearly two-thirds of patients who entered the Phase 3 study after the hold was resolved and enrollment resumed," CytRx reported.
The clinical hold took place in November 2014, and CytRx attributes its shortcomings of its Phase 3 trials directly to the hold.
The unforeseen clinical hold that interrupted this study impacted the outcome of the current evaluation, underscoring a need for a subsequent analysis. " said Daniel Levitt, executive vice president and chief medical officer of CytRx.
CytRx said it "expects to conduct a second analysis … and to announce the results of this evaluation and hold an end-of-Phase 3 meeting with the Food and Drug Administration (FDA) in the fourth quarter of 2016. "
Shares of CytRx have plunged nearly 62 percent in 2016. The company hit a new 52-week low of 74 cents per share Tuesday.